Viewing StudyNCT04154943



Ignite Creation Date: 2024-05-06 @ 1:54 PM
Last Modification Date: 2024-10-26 @ 1:21 PM
Study NCT ID: NCT04154943
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2023-02-08
First Post: 2019-11-05

Brief Title: Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
Sponsor:
Organization: Regeneron Pharmaceuticals

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 79
Enrollment Type: ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE2
Observational Models:
Time Perspective List:
Who Masked List: